<DOC>
	<DOCNO>NCT01018745</DOCNO>
	<brief_summary>The purpose clinical study establish maximum tolerate dose ( MTD ) recommend Phase 2 dose ( dose range appropriate ) BMS-907351 ( XL184 ) administer orally daily schedule subject advance metastatic solid tumor .</brief_summary>
	<brief_title>Multiple Ascending Dose Study BMS-907351 ( XL184 ) Patients With Solid Tumors Japan</brief_title>
	<detailed_description />
	<criteria>Advanced metastatic solid tumor standard care ineffective inappropriate Life expectancy least 3 month Eastern Cooperative Oncology Group performance 02 Subject uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>